viernes, 26 de septiembre de 2014

EBioMedicine welcoming submissions!

EBioMedicine welcoming submissions!

EBioMedicine welcoming 

Dear Colleague,

Submit your paper

The Lancet

Cell Press

EBioMedicine is now live! EBioMedicine is a new,
unique online, open-access journal from Elsevier,
covering the entire spectrum from basic science to
clinical researchwith editorial support from The Lancet
and Cell Press.
As Chief Editors of EBioMedicine we invite you to
submit your paper for publication in the journal, where
your work will be seen and discussed across disciplines.
Our intention is for EBioMedicine itself to be 'translational',
 in that our primary goal is to help translate your clinically
relevant research insights into practical tools for the betterment
of human health – by publishing quality basic biomedical
and clinical research and by serving as a centralized forum
for the discussion and dissemination of these important research findings.
In the words of our Advisory Board member, Ronald A. DePinho, 
President, MD Anderson Cancer Center; Professor, 
Cancer Biology:
"We have entered an era where bench is at bedside, 
providing unprecedented opportunities to convert 
fundamental discoveries into clinical endpoints. To realize the 
full potential of the opportunity, EBioMedicine seeks to foster 
integration across the worlds of basic and clinical research with 
the goal of improving human health".
Benefits of submitting your paper:
- High quality, open access journal that bridges the entire continuum between basic biomedical and clinical research
- Acceptance to online publication in 48 hours
- High quality peer-review
- High visibility of your article with Open Access and extra PR
We cordially invite you to submit your research for
publication in our inaugural issue in October.
We would also like to take this opportunity to introduce
our international advisory board members.
To find out more about the journal scope and
We look forward to working with you on this exciting venture!

Julie Stacey & Duc Le
Editors in Chief, EBioMedicine

No hay comentarios:

Publicar un comentario